Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio

Fineline Cube Jan 23, 2026
Company Deals

TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China

Fineline Cube Jan 23, 2026
Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Fineline Cube Jan 22, 2026
Company Deals

Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline

Fineline Cube Jan 22, 2026
Company Deals

AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Enhertu Wins China NMPA Approval for Second‑Line HER2‑Positive Gastric Cancer

Fineline Cube Jan 22, 2026
Company Drug

AstraZeneca’s Imfinzi Wins China Approval for Endometrial Cancer, Securing Seventh Indication

Fineline Cube Jan 22, 2026
Company Medical Device

MicroPort CardioFlow Medtech’s VitaFlow Liberty Receives CE Mark for European Expansion

Fineline Cube Apr 26, 2024

China-based MicroPort Scientific Corp (HKG: 0853), a leading medical device company, announced that its spin-off,...

Company Deals

Allgens Medical Technology to Acquire German Dental Implant Maker HumanTech Dental for EUR 3.25 Million

Fineline Cube Apr 26, 2024

Beijing-based Allgens Medical Technology Co., Ltd (SHA: 688613), specializing in regenerative medicine materials and implantable...

Company Drug

Wuhan Bio-Raid Biotechnology Secures NMPA Approval for First-in-Class CD99-Targeted CAR-T Therapy

Fineline Cube Apr 26, 2024

Wuhan Bio-Raid Biotechnology Co., Ltd, a leading developer of chimeric antigen receptor (CAR)-T cell therapies...

Company

Clover Biopharmaceuticals Reports First Commercial Sales and Narrows Annual Loss in 2023

Fineline Cube Apr 26, 2024

China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced its financial results for 2023, recording its...

Company

JW Therapeutics Reports 19.3% YOY Revenue Growth in 2023, Driven by CAR-T Therapy Carteyva

Fineline Cube Apr 26, 2024

China-based JW Therapeutics (HKG: 2126) has announced its financial results for 2023, with revenues reaching...

Company

MSD Reports USD 15.8 Billion in Q1 2024 Sales, Marked by 11% YOY Growth Excluding Forex Impact

Fineline Cube Apr 26, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has released its financial report for the first...

Company

Hua Medicine Reports 2023 Revenues of RMB 76.6 Million, Driven by Hypoglycemic Agent HuaTangNing

Fineline Cube Apr 26, 2024

China-based biopharmaceutical company Hua Medicine (HKG: 2552) has released its financial report for 2023, with...

Company Deals

Yantai Lannacheng Biotech Secures RMB 300 Million in Series B+ Financing Round

Fineline Cube Apr 26, 2024

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced that its controlling subsidiary, Yantai...

Company

Huadong Medicine’s Lidocaine-Containing Hyaluronic Acid Gel Accepted for NMPA Review

Fineline Cube Apr 26, 2024

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration...

Policy / Regulatory

China’s NHC to Assume Management of Human Genetic Resources from May 2024

Fineline Cube Apr 26, 2024

The National Health Commission (NHC) of China has announced that the State Council has approved...

Company Drug

Chia Tai Tianqing’s TQA3038 siRNA Drug Completes Phase I Clinical Trial for Chronic Hepatitis B

Fineline Cube Apr 26, 2024

Chia Tai Tianqing has announced the successful completion of a Phase I clinical study for...

Company Drug

US FDA Greenlights Henlius Biotech’s Hanquyou as Biosimilar to Roche’s Herceptin

Fineline Cube Apr 26, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696) has achieved a significant milestone with the US Food...

Company

Sanofi Reports 6.7% YOY Sales Growth in Q1 2024, Driven by Dupixent and New Product Launches

Fineline Cube Apr 26, 2024

France-based pharmaceutical giant Sanofi (NASDAQ: SNY) has reported its financial results for the first quarter...

Company Drug

Novartis Receives Positive Interim Results for Antimalarial Coartem in Infants

Fineline Cube Apr 26, 2024

Swiss pharmaceutical company Novartis (NYSE: NVS) has announced interim results from a Phase II/III clinical...

Company

Bristol Myers Squibb Reports 6% YOY Revenue Growth in Q1 2024, Driven by Eliquis and Reblozyl

Fineline Cube Apr 26, 2024

Pharmaceutical giant Bristol Myers Squibb (BMS; NYSE: BMY) has reported a 6% year-on-year (YOY) increase...

Company

Roche’s Q1 2024 Turnover Rises 2% YOY, Driven by New Medicines and Diagnostics

Fineline Cube Apr 25, 2024

Swiss pharmaceutical and diagnostics giant Roche (SWX: ROG) has reported a 2% year-on-year (YOY) increase...

Company

Gan & Lee Pharmaceuticals Reports 52.31% YOY Revenue Growth in 2023, Driven by Insulin Sales

Fineline Cube Apr 25, 2024

Gan & Lee Pharmaceuticals (SHA: 603087) has announced its financial results for 2023, reporting a...

Company Policy / Regulatory

Novartis Becomes First MNC to Publicly Adjust China CRDMO Partnerships in Response to BioSecure Act

Fineline Cube Apr 25, 2024

Swiss pharmaceutical giant Novartis (NYSE: NVS) has reportedly become the first multinational corporation to publicly...

Company Deals

Insilico Medicine Partners with invoX Pharma to Boost AI-Driven Drug Discovery

Fineline Cube Apr 25, 2024

China’s generative artificial intelligence (AI)-driven biotech firm Insilico Medicine has entered into a partnership with...

Company Drug

Hebei Changshan Biochemical’s Albenatide File for Type 2 Diabetes Accepted by China’s NMPA

Fineline Cube Apr 25, 2024

Hebei Changshan Biochemical Pharmaceutical Co., Ltd (CSBIO; SHE: 300255) has announced that the National Medical...

Posts pagination

1 … 316 317 318 … 613

Recent updates

  • Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio
  • TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China
  • China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy
  • Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline
  • AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio

Company Deals

TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China

Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Company Deals

Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.